Fig. 3
No change in microglia and astrocyte markers in lumbar spinal cord between isotype control and anti-HMGB1 antibody treated SOD1G93A mice. SOD1G93A mice were intraperitoneally injected weekly with the anti-HMGB1 antibody at 35 days of age (100 μg). Major non-neuronal cell populations (microglia/monocytes and astrocytes) in vehicle and anti-HMGB1-treated SOD1G93A mice were investigated at mid-symptomatic stage of disease (133 days) using quantitative PCR and immunohistochemistry. a–c Shows anti-HMGB1 treatment had no effect on microglia (Itgam, Cd68 and Aif1) mRNA transcript levels (n = 6, p > 0.05, Student’s t test). d Shows a reduction in monocyte (Ly6c) mRNA transcript levels in anti-HMGB1-treated SOD1G93A mice when compared to isotype control-treated SOD1G93A mice (n = 6, * P < 0.05, Student’s t test). e Shows representative images of CD11b-positive microglia in the lumbar spinal cord of isotype control and anti-HMGB1-treated SOD1G93A mice at 133 days of age. Dashed line shows the outline of the ventral horn with higher magnification of the white square. Scale bar = 100 μm. f, g Shows no change in microglia expression and activated microglia (amoeboid) in anti-HMGB1-treated SOD1G93A mice compared with isotype control-treated SOD1G93A mice (n = 4, p > 0.05, Student’s t test). h Shows no change in astrocyte (Gfap) mRNA transcript levels between isotype control and anti-HMGB1-treated SOD1G93A mice (n = 6, p > 0.05, Student’s t test). i Show representative images of GFAP-positive astrocytes in the lumbar spinal cord of isotype control and anti-HMGB1-treated SOD1G93A mice at 133 days of age. Dashed line shows the outline of the ventral horn with higher magnification of the white squares. Scale bars = 100 μm. j Shows no change in astrocyte expression in anti-HMGB1 treated-SOD1G93A mice compared with isotype control-treated SOD1G93A mice (n = 4, p > 0.05, Student’s t test). Data are presented as mean ± SEM